The serotonin 5-HT 1B receptors regulate the release of serotonin and are involved in various disease states, including depression and schizophrenia. The goal of the study was to evaluate a high affinity and high selectivity antagonist, [
Introduction
Functional abnormalities of the 5-HT system have been linked to a variety of psychiatric disorders, including anxiety [1] [2] [3] depression [4] , and schizophrenia [5, 6] . The serotonin 5-HT 1B receptors, located on the 5-HT neurons, are autoreceptors involved in the regulation of synaptic 5-HT concentrations [7] . As a result, these receptors are a target for pharmaceutical development for their potential in the treatment of multiple psychiatric disorders, including anxiety, depression and substance abuse [8] [9] [10] [11] . It has been suggested that selective blocking of the 5-HT 1B receptors in the brain could pave the way for a novel approach for managing psychiatric disorders [6, 12] . For example, in animal models, blockade of the terminal 5-HT 1B receptors with an antagonist has been demonstrated to increase synaptic 5-HT concentration [13, 14] . In light of these observations, 5-HT 1B antagonists, either alone or in combination with selective serotonin reuptake inhibitors (SSRIs), may hold potential as rapid-onset antidepressants. Thus, imaging the 5-HT 1B receptors in vivo will aid in the elucidation of 5-HT 1B receptor functions, and in the development of novel antidepressants.
P943, R-1-[4-(2-methoxy-isopropyl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)benzyl]-pyrrolidin-2-one, is a potent 5-HT 1B antagonist in vitro, which binds with high affinity to the human 5-HT 1B receptor expressed in HeLa cells (K i =0.77 nM). The affinity of P943 for other 5-HT and non-5-HT receptors is at least 100-fold lower, making this a highly 5-HT 1B -selective ligand (e.g. K i =85 nM for 5-HT 1A receptors) [15, 16] . Its specificity and selectivity was characterized by in vitro autoradiography studies, showing localization of radioactivity in regions known to contain high levels of the 5-HT 1B receptor (e.g., globus pallidus and substantia nigra). Specific binding to these slices was demonstrated by co-incubation of the radiotracer with 10 μM serotonin. No specific accumulation was observed in the cerebellum, a region known to be devoid of 5-HT 1B receptors. Specific displacement of the radiotracer was achieved using a structurally unrelated, but selective 5-HT 1B inhibitor (CP-448,187). Its antagonist disposition was demonstrated in vitro in guinea pig substantia nigra, by blocking the reduction of 5-HT 1B agonist-induced adenylate cyclase activities. The enantioselectivity of P943 has also been shown via ex vivo autoradiography studies in guinea pig [15, 16] . The details of these in vitro and in vivo screening and comparative studies will be published elsewhere. A summary of the in vitro pharmacology profile for unlabeled P943, which was performed by the National Institute of Mental Health (NIMH) Psychoactive Drug Screening Program, is shown in Table 1 , demonstrating its potency and selectivity towards 5-HT 1B receptors.
The aim of the present study was to carry out pre-clinical evaluation of [ 11 C]P943 in non-human primates with the high resolution research tomography (HRRT) positron emission tomography (PET) scanner. For initial quantitative evaluation, the binding potential (BP ND ) was calculated using the equilibrium ratios of regions to cerebellum, assuming this region is devoid of 5-HT 1B receptors. The saturability and specificity of the tracer binding was assessed by blocking studies with unlabeled parent compound and GR127935 (a selective 5-HT 1B /5-HT 1D antagonist). Here, we report the preparation of [ 11 C]P943 and its evaluation in non-human primates to assess its in vivo characteristics.
Materials and methods

General
Reagents and solvents were purchased from the standard commercial sources, i.e., Sigma-Aldrich, Fisher Scientific, Merck or J. T. Baker, and were used without purification. Both the P943 standard and the N-desmethyl-precursor were provided by Pfizer.
Synthesis of [
11 C]P943 was carried out either with a TRACERLab FxC automated synthesis module (GE Medical Systems), or with a AutoLoop (Bioscan, Washington, DC, USA). For the FxC module, the radioligand was purified by a preparative high-performance liquid chromatography (HPLC) system that is included with, and integrated into, the module. It consists of a Syknm solvent delivery system, injection valve, and a radioactivity flow-through detector operating in series with a UV detector (254 nm). The latter is a WellChrom Filter-Photometer K2001 with deuterium lamp containing 4 wavelength filters: 200, 220, 254 and 280 nm. For the AutoLoop, a KNAUER UV detector (254 nm) was used, operating in series with the AutoLoop's gammadetector that is included within the product module, along with a Shimadzu LC-20AT solvent delivery system.
For both synthesis modules, the purification of the product was achieved by using a semi preparative HPLC column [Phenomenex's Luna C18(2), 10μ, 250×10 mm]. The column was eluted under isocratic conditions with a mobile phase composed of 40:60 (v/v) acetonitrile/0.1 M ammonium acetate buffer of pH 5.5 (with acetic acid) and a flow rate of 5 ml/min. [18, 19] at 190°C, and the resulting [ 11 C]methyl triflate was bubbled into a solution of desmethyl P943 (1 mg) in 400 ml of anhydrous dimethylformamide (DMF) cooled at -30°C until activity peaked. The resulting solution was then heated at 100°C for 4 minutes. The reaction mixture was cooled down to 80°C, then diluted with 1.3 ml of deionized water and injected onto the semi preparative HPLC column. The radioactivity fraction eluting between 10-12 min was collected, diluted with 50 ml of water, and loaded onto a Waters Classic C18 Sep-Pak cartridge. The Sep-Pak was rinsed with 10 ml of 1 mM HCl, then eluted with 1 ml of USP absolute ethanol (Pharmco, USP) into the FxC's intermediate product vessel that contained a stirring mixture of 7 ml saline (USP, American Regent) N 2 ) . After activity peaked in the loop, the reaction mixture was allowed to stand at ambient temperature for 5 min and then injected onto the semi-preparative column. The product fraction was collected and diluted with 50 ml deionized water, and loaded onto a C18 Sep-Pak. The Sep-Pak was rinsed with 10 ml of 1 mM HCl, and then eluted with 1 ml of USP absolute ethanol followed by 3 ml of saline. The combined eluent was passed through a sterile 0.2 mm membrane filter (33 mm, Millipore MILLEX GV) into a sterile and vented dose vial containing 7 ml saline and 40 ml of 4.2% sodium bicarbonate.
Radiochemistry
Synthesis and formulation of (
R)-1-(4-(2-methoxy- propan-2-yl)phenyl)-3-(2-(4-methylpiperazin-1-yl)benzyl) pyrrolidin-2-one ([ 11 C]P943) Radioisotope C-11
Determination of radiochemical purity and specific activity
The final product was analyzed by radio-HPLC coupled with a gamma detector. A Shimadzu LC-20AT Prominence system was used, which is equipped with a SPD-M20A Diode Array (PDA) detector or SPD-20A UV/Vis detector (254 nm) also operating in series with a Bioscan Flow-Count g-detector. A Jones Genesis C18 4μm 4.6×250 mm analytical column was used, eluted under isocratic conditions with mobile-phase system composing of 40:60 (v/v) acetonitrile/0.1 M ammonium formate buffer of pH 4.2 (with acetic acid) and a flow rate of 2 ml/min. The specific activity for [
11 C]P943 was determined by counting an aliquot in a dose calibrator and determining the mass by HPLC against a calibration curve of the cold standard. Identity was confirmed by a coinjection with the standard.
Brain PET imaging in non-human primates
PET studies were performed according to a protocol approved by the Yale University Institutional Animal Care and Use Committee.
General imaging procedure
PET imaging of the brain distribution of [ 11 C]P943 was carried out in Rhesus monkeys weighing 5-8 kg. Each animal (fasted overnight) received ketamine (10 mg/kg im) and glycopyrrolate (0.005-0.01 mg/kg im), and iv catheters (infused with normal saline) were inserted in extremity veins for administration of fluids, drugs, and PET radiotracers and for blood sampling. Endotracheal intubation was performed to permit administration of gaseous anesthetics, and isoflurane (∼2% isoflurane) was administered to effect.
The monkey's head was positioned in the tomograph using a custom-designed stereotaxic headholder and was then imaged with a brain-dedicated high-resolution research tomography HRRT (207 slices with 1.2 mm slice separation, resolution ∼3 mm FWHM in 3D acquisition mode) PET scanner (Siemens, Knoxville, TN, USA) [20] . The animal was attached to a physiological monitor, and vital signs (pulse rate, blood pressure, respirations, electrocardiogram) were continuously monitored. pCO 2 was monitored with an end-tidal monitor, and body temperature with a rectal probe. A transmission scan was obtained before the emission scan for attenuation correction. An average of radioactive dose of 5-7 mCi of [ 11 C]P943 was administered at the time of injection. In studies for which a continuous infusion paradigm was used, a computer-controlled pump (Harvard Instruments) was employed. List mode data were acquired for 120-min duration and reconstructed into dynamic images with a cluster-based iterative reconstruction algorithm [21] with corrections for attenuation, scatter, randoms, deadtime and decay. Blood samples were drawn to measure the time course of radiotracer and its radioactive metabolites in blood.
Plasma free fraction measurement
The plasma free fraction (f P ) was determined by ultrafiltration of triplicate 0.2-ml aliquots of plasma mixed with the radiotracer. The separation of the protein-bound fraction from the unbound fraction (i.e., free fraction) of the radioactivity in the plasma was achieved by using ultrafiltration tubes (Centrifree UF device number 4104, Millipore, Billerica, MA, USA) and centrifugation (1100g for 20 min; IEC Medilite centrifuge, Thermo Fisher Scientific, Waltham, MA, USA). f P was calculated as the ratio of the concentration (radioactivity/ml) of the filtrate to that of the total.
Determination of ligand metabolism in plasma
For selected samples (10, 20 40, 60 and 90 min postinjection) plasma proteins were precipitated using acetonitrile (1 ml/ml plasma) and the mixture was centrifuged (14000×g for 4 min; minispin plus centrifuge, Eppendorf, Westbury, NY, USA) to separate the supernatant from the pellet. An aliquot (0.2 ml) of the supernatant was counted in a well-counter and the rest was analyzed by reverse-phase HPLC. The HPLC system consisted of an isocratic pump (AT-20A, Shimadzu, Kyoto, Japan), an injector (7725i, Rheodyne, Rohnert Park, CA, USA) equipped with a 2 ml sample loop, a C18 Symmetry preparative column (7.8×300 mm, 7 μm, Waters, Milford, MA, USA). The column was eluted with acetonitrile and aqueous 50 mM ammonium acetate pH 5.8 (55/45) at a flow rate of 2.8 ml/min. The output of the HPLC column was connected to a fraction collector (CF-1 Fraction Collector, Spectrum Chromatography, Houston, TX, USA). Fractions were collected every minute and counted in a well counter (Wizard, Perkin Elmer). Parent fraction was determined as the ratio of radioactivity in [
11 C]P943-containing fractions to total injected activity.
Image analysis
Magnetic resonance (MR) images were acquired on each monkey with a 3T scanner to assist with anatomical localization of regions of interest (ROIs). A T1-weighted coronal MR imaging (MRI) sequence was used (TE=3.34, TR=2530, 176 slices, slice thickness=0.54 mm, flip angle=7 degrees, image matrix=256×256, pixel size=0.5×0.5, FOV=140 mm, 3D turbo flash). The following ROIs were defined on the MR images: caudate, cingulate, occipital, frontal, insula, globus pallidus, putamen and thalamus. Summed PET images were registered to the individual MRIs using a 6-parameter affine mutual information algorithm. To generate each regional time-activity curve (results expressed as KBq/ml), the mean radioactivity in the ROI was calculated for each frame and plotted versus time. For infusion scans at equilibrium, to calculate binding potential (BP ND ), the mean concentration from 70-100 minutes in each ROI was divided by the mean concentration during the same time period in the reference region (cerebellum), and a value of one was subtracted from this ratio. BP ND images were calculated in the same way using pixelby-pixel calculations.
Experiment design 2.4.1. Baseline study
A 2 hr baseline scan with a bolus injection of [ 11 C]P943 was carried out in one monkey to determine the biodistribution and kinetics of the tracer in the brain. Baseline scans using a bolus injection followed by constant infusion (B/I) paradigm were also performed with bolus component (K bol ) of 150 min in a total of four monkeys. The algorithm used to choose an optimum value of K bol has been described previously [22] .
Binding saturability study
Six [ 11 C]P943 scans were acquired in 2 different anesthetized rhesus monkeys (a total of 12 scans). For each study day, 3 scans were performed at high, medium, and low specific activities (SA), depending on the amount of unlabeled (cold) P943 added to the injection syringe. Each animal was studied on two days, so six scans were acquired per animal using different levels of SA. All injections were iv bolus (2 min) plus constant infusion (118 min) delivered by an automatic pump program. The relative fraction of the dose delivered in the bolus varied for each of the 3 scans (K bol =150 min for the high SA scans; K bol =120 for the medium SA scans; K bol =105 for the low SA scans), since a smaller bolus component is necessary for lower SA scans.
Binding potentials (BP ND ) were determined by the equilibrium ratios of the radioactivity concentrations in the ROIs to that in the cerebellum (minus 1). The saturability of the tracer binding was assessed by comparing the BP ND values between the high SA scan (baseline), and medium and low SA scans (i.e., self-blocking scans) of the tracer binding. Kinetic modeling and estimation of B max (receptor density) and K d (dissociation constant) will be published elsewhere [23] .
Binding selectivity study
The selectivity of [ 11 C]P943 binding towards the 5-HT 1B receptor was examined in two rhesus monkeys by blocking with GR127935 (a selective 5-HT 1B /5-HT 1D antagonist). A control scan was first obtained following a B/I administration of [ 11 C]P943. GR127935 (2 mg/kg, bolus, iv) was administered 15 min prior to tracer injection in the second scan, in which the same bolus injection plus constant infusion paradigm (K bol =150 min) was used.
Results and discussion
Chemistry
[ 11 C]P943 contains a piperazine side chain that is common in 5-HT 1B antagonists [11] . N-Alkylation of the normethylpiperazine moeity of the pyrrolidinone precursor 1 (1-(4-(2-methoxypropan-2-yl)phenyl)-3-(2-(piperazin-1-yl)benzyl) pyrrolidin-2-one) was carried out with [ 11 C]methyl triflate in DMF at 100°C for 4 min (Fig. 1, Method A) in the FxC module. Theaverage radiochemical yield was aprox.10±2% at the end of synthesis (based on trapped [ 11 C]methyl triflate) with a specific activity of 326±133 MBq/nmol (8.8±3.6 mCi/ nmol) calculated at the end-of-synthesis (n=37). On the AutoLoop, radiolabeling was accomplished with [ 11 C] methyl iodide at ambient temperature for 5 minutes (Fig. 1,  Method B) ; yields and specific activity were slightly lower. Both radiolabeling methods produced [ 11 C]P943 in radiochemical purity of N99%.
Baseline study
The time-activity curves for a 2-h baseline scan with a bolus injection of [ 11 C]P943 are presented in Fig. 2 . The regional uptake of the tracer was shown to be consistent with the known distribution of 5-HT 1B receptors in the brain: highest in the globus pallidus and occipital cortex; moderate in other cortical areas, basal ganglia, and thalamus; and lowest in the cerebellum. Peak uptake was reached between 10-30 min in most brain regions with relatively fast kinetics.
In the process of determining the ligand metabolism in plasma, we found the percentage of radioactivity recovered in the supernatant was 96±1% at the beginning of the scan and 92±1% at the end of the scan. The amount of radioactivity in plasma representing unchanged radioligand was 96%, 85%, 71%, 56%, 42% and 32% at 0, 10, 20, 40, 60 and 90 min, respectively (Fig. 3, averaged over 25 scans) . No lipophilic, labeled metabolite was observed. The mean (n=25) plasma free fraction was ∼23%.
Baseline scans using a bolus injection followed by constant infusion (B/I) paradigm were performed in several monkeys with bolus component (K bol ) of 150 min [please note: since a smaller bolus component is necessary for lower SA scans, a value of K bol 120 and 105 was applied for the medium and low SA scans, respectively, as shown in Fig. 4(A) and (B) ]. The mean baseline BP values across regions from a total of 10 baseline scans are presented in Table 2 . The time-activity curves for a representative bolus plus infusion baseline scan is presented in Fig. 5(A) .
Binding saturability study
Saturability of [
11 C]P943 binding studies were performed with 3 bolus plus infusion deliveries of [ 11 C]P943 per day on 1-2 days. SA was varied from 2-200 MBq/nmol (0.05-5 mCi/nmol) by adding various amount of unlabeled (cold) P943. Binding potential (BP ND ) was calculated using the equilibrium ratio of regions to cerebellum. Equilibrium was reached by ∼70 min (see the time-activity curves for a representative bolus plus infusion baseline scan presented in Fig. 5(A) , equilibrium was reached by ∼70 min in the brain) and data from 70-100 min were used to calculate BP ND . The binding potentials BP ND at high specific activity ranged from 0.25 to 0.75, with the highest values of 0.80 and 0.57 in the occipital cortex and globus pallidus, respectively. The uptake of [ 11 C]P943 in the 5-HT 1B receptor rich regions was reduced in a dose-dependent manner by adding various amount of unlabeled (cold) P943, i.e., self-block ( Fig. 4A  and B) . Each of the BP ND values presented in the bar graph of Fig. 4A 
Binding selectivity study
A paired study was done in two rhesus monkeys using a constant infusion paradigm. Initially, a control study was a BP ND was calculated by the mean concentration from 70-100 min in each ROI divided by the mean concentration during the same time period in the reference region (cerebellum), and a value of 1 was subtracted from this ratio. The mean baseline BP ND values across regions were derived from a total of 10 baseline scans using the bolus plus infusion paradigm. performed. Three hours later a second study was performed starting 5 min after i.v. administration of the 5-HT 1B antagonist GR127935 (2 mg/kg). Similar mass and activity between the control and blocking scans were injected (i.e., a radioactive dose of 5.4±0.7 mCi of [ 11 C]P943 was administered with a specific activity at time of injection of 6.3±0.9 mCi/nmol for the two pair studies). The time-activity curves for target regions and the reference region (CB) before and after blockade are displayed in Fig. 5A and B, respectively. The parametric images of binding potentials Monkey 1  47  96  76  78  84  80  66  61  Monkey 2  33  94  74  45  98  66  61  45  Mean  40  95  75  62  91  73  64  53 a A paired study (baseline study followed by a blocking study with three hour separation of injections) was performed in two rhesus monkeys using a constant infusion paradigm. The 5-HT 1B antagonist GR127935 (2 mg/kg iv) was administered 5 min prior to the beginning of the second tracer injection. before and after blockade, along with the corresponding MRI slices, are shown in Fig. 6A -C, respectively. GR127935 resulted in reduction of BP ND values by 42-95% across regions (averaged from two blocking studies in two monkeys) with a near complete displacement of [ 11 C]P943 from the occipital and frontal regions of the brain (reduction of the BP ND values from 0.71 to 0.03 and 0.49 to 0.06 for occipital and frontal cortex, respectively). However, the lack of full blockade in putamen and insula was observed ( Table 3) . The difference in the calculated % blockade between regions may be due in part to regional variations in the level of nonspecific binding.
Discussion
P943 is a 5-HT 1B receptor antagonist with physiochemical properties suitable for use as a PET radiotracer. A series of preclinical and clinical assessments performed at Uppsala Imanet, Sweden confirmed that [
11 C]P943 is a suitable tracer for in vivo evaluations of the 5-HT 1B receptor system [15, 16] . Here we report the radiolabeling of [
11 C]P943 that was carried out at the Yale PET Center using automated synthesis modules. Both the GE TRACERLab FxC automated synthesizer and Bioscan AutoLoop produced the tracer in high radiochemical yields and with high specific activities.
Our PET studies in rhesus monkeys have shown [ 11 C] P943 to enter the brain readily. The regional pattern in the brain correlates well with autoradiographic determinations: highest uptake in globus pallidus and occipital cortex, areas known to have high concentrations of the 5-HT 1B receptor; and a low uptake in the cerebellum, an area known to be devoid of this receptor [24] . The labeled metabolites obtained were more polar (less lipophilic) than the parent tracer, and therefore unlikely to cross the blood-brain barrier and contribute to the brain activity.
It is important to note that a bolus plus constant infusion paradigm was applied to the current tracer evaluation study for [
11 C]P943. In principle, for reversible ligands, a transient equilibrium can be reached after a bolus injection; however, depending on the rate of plasma clearance and the local tissue kinetics, tissue-to-plasma and tissue-to-reference ratios will be biased. A straightforward approach to eliminate the biases of transient equilibrium measures is to maintain constant blood and tissue concentrations by administering radioactivity as a programmed infusion instead of a bolus. This approach has been used to produce true equilibrium for receptor studies so that V T and BP can be measured directly and reliably [22] . In this study, we defined the infusion schedule to consist of a combination of bolus and continuous infusion. This infusion paradigm facilitated the quantitative evaluation of [ 11 C]P943, as the equilibrium was reached by ∼70 min. Binding potentials (BP ND ), can simply be determined by the equilibrium ratios of ROIs to cerebellum (minus 1), based on the data from 70 to 100 min.
The saturability of the tracer binding was supported by a dose-dependent reduction of binding potentials in brain regions by carrying out self-block experiments with the unlabeled parent compound, P943. By adding various amount of cold P943 to the tracer to generate the injection dose with high, medium, and low specific activities, the degree of blocking of the tracer binding to the receptor can then be determined.
Based on the recent literature, the serotonergic system is complex; to date, 14 different serotonin receptors have been distinguished within the serotonin receptor family: 5-HT 1A , 5-HT 1B , 5-HT 1D , 5-HT 1E , 5-HT 1F , 5-HT 2A , 5-HT 2B , 5-HT 2C , 5-HT 3 ,5-HT 4 , 5-HT 5A , 5-HT 5B , 5-HT 6 and 5-HT 7 [25] . Only recently the 5-HT 1B receptor has been distinguished from the 5-HT 1D receptor; however, there has been much debate about the nomenclature and classification of the 5-HT 1B receptor [26] . The in vitro pharmacology profile for unlabeled P943 is shown in Table 1 , demonstrating its potency and selectivity towards 5-HT 1B ; however, no assay was performed for its selectivity towards 5-HT 1B vs. 5-HT 1D as there is no drug selective only for 5-HT 1B or 5-HT 1D. GR127935 is a potent and effective antagonist for human 5-HT 1D and 5-HT 1B with a pK i value of 9.0 and 8.6 for 5-HT 1B and 5-HT 1D , respectively [27] [28] [29] . In our blocking study with GR127935, a near complete blockade of [ 11 C]P943 binding was observed after pretreatment with GR127935. Due to the lack of available pharmacological tools specifically for 5-HT 1B and 5-HT 1D receptor subtypes [30, 31] , it is difficult to distinguish whether or not [ 11 C]P943 also binds to 5-HT 1D receptor in vivo. However, in vitro binding assays indicate that binding affinity of P943 is much higher for 5-HT 1B than that for 5-HT 1D (Table 1) . Furthermore, the autoradiograms indicated that the 5-HT 1B receptor is much more abundant than the 5-HT 1D receptor in the human brain, the latter seeming to occur only in low amounts mainly in the ventral pallidum [32] .
The affinity of P943 for 5-HT 1B is 50-100 times higher than that for 5-HT 1A receptors based on the in vitro data (K i =62 nM and 1.2 nM for 5-HT 1A and 5-HT 1B, respectively, based on Table 1 Based on these assessments, our studies demonstrate that [ 11 C]P943 is a suitable PET ligand for imaging 5-HT 1B receptors.
The results from the preclinical in vitro evaluation study and our in vivo PET imaging studies in non-human primates and humans have been presented as abstracts at several conferences [15,35a,35b] . Kinetic modeling methods were recently presented [36a,36b] . Recently, a new PET ligand, [ 11 C]AZ10419369 developed by Astra Zeneca Pharmaceuticals also showed promising results [24] . Its selectivity was demonstrated via an in vitro blocking study with the same 5-HT 1B/1D antagonist GR 127935 used in the present study. It is important to point out that the Astra Zeneca group used only the bolus injection paradigm for their non-human primate studies; however, a bolus plus constant infusion paradigm was applied to the current tracer evaluation study for [ 11 C]P943. Based on the limited results from the bolus injection paradigm of the two groups, the two tracers appear to have similar brain uptake and similar values for the ratio of the (target) tissue to reference tissue concentration [36a] . A careful comparison of [
11 C]P943 and [ 11 C]AZ10419369 will be facilitated by the publication of modeling studies for both tracers. SB-616234-A (1-[6-(cis-3,5-Dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[20-methyl-40-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride) also looks promising based on the in vitro and behavior characterization data; however, its in vivo specificity has not been evaluated yet [37, 38] .
Conclusion
[ 11 C]P943 is a suitable ligand for PET imaging studies of 5-HT 1B receptors in vivo. This ligand has been advanced to imaging applications in humans and it will be a useful new tracer for studying the functional significance of 5-HT 1B receptors in humans and its role in various disease states.
